Table 3 IC50 of DOX in different vehicles to MCF7, MCF7/adr and H22 cells (n = 3).

From: Cationic Polymethacrylate-Modified Liposomes Significantly Enhanced Doxorubicin Delivery and Antitumor Activity

Vesicles

IC50

MCF7 (μg/ml)

MCF7/adr (μg/ml)

H22 (nM)

Free DOX

0.90 ± 0.05

13.90 ± 3.55

15 ± 1

DOX-LP

0.91 ± 0.32

24.07 ± 2.18*b

12 ± 1

DOX-ERLP

0.63 ± 0.10*a

6.72 ± 2.53*c,**d

6 ± 0.5**e,**f

  1. P < 0.05: *P < 0.01: ** aP < 0.05, DOX- solution vs DOX-ERLP; cP < 0.05, DOX- solution vs DOX-LP; cP < 0.05, DOX- solution vs DOX-ERLP; dP < 0.01, DOX-LP vs DOX- ERLP; eP < 0.01, DOX- solution vs DOX-ERLP; fP < 0.01, DOX-LP vs DOX- ERLP.
Back to article page